HIV-1 p55/p17 Antibody (1B2): sc-57828

HIV-1 p55/p17 Antibody (1B2) is a mouse monoclonal IgG1 antibody that detects HIV-1 p55/p17 protein of HIV-1 origin by western blotting (WB), immunofluorescence (IF), and flow cytometry (FCM). Anti-HIV-1 p55/p17 antibody (1B2) is available in both non-conjugated and various conjugated forms, including fluorescein isothiocyanate (FITC), providing flexibility for different experimental needs. HIV-1 p55/p17 protein plays a crucial role in the viral life cycle, particularly as p17, a structural matrix protein, is essential for the assembly and release of new virions. Located at the inner surface of the viral envelope, p17 facilitates the transport of viral nucleocapsids from the nucleus to the plasma membrane, where viral assembly occurs. This process is vital for virus propagation, ensuring newly formed virions are efficiently released to infect other cells. Additionally, p17 is implicated in HIV-1 pathogenesis, as the presence of anti-p17 antibodies serves as a serological marker for disease progression, highlighting p17′s potential as a target for therapeutic interventions and immunizations against HIV-1. Understanding the function and significance of HIV-1 p55/p17 protein is essential for developing effective strategies to combat HIV infection and associated diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HIV-1 p55/p17 Antibody (1B2) References:

1. Immunodominant epitopes of HIV-1 p17 and p24.  |  Graham, S., et al. 1992. AIDS Res Hum Retroviruses. 8: 1781-8. PMID: 1280955
2. Specific antibody responses to synthetic peptides of HIV-1 p17 correlate with different stages of HIV-1 infection.  |  Jiang, JD., et al. 1992. J Acquir Immune Defic Syndr (1988). 5: 382-90. PMID: 1372353
3. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.  |  Fiorentini, S., et al. 2004. Biopolymers. 76: 334-43. PMID: 15386266
4. Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30.  |  Boucher, CA., et al. 1990. J Clin Lab Anal. 4: 43-7. PMID: 1690277
5. Cellular aspartyl proteases promote the unconventional secretion of biologically active HIV-1 matrix protein p17.  |  Caccuri, F., et al. 2016. Sci Rep. 6: 38027. PMID: 27905556
6. Expression, Purification and Characterization of Hiv-1 Capsid Precursor Protein p41.  |  Zhang, Z., et al. 2018. Protein J. 37: 194-202. PMID: 29508209
7. HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.  |  Sarin, PS., et al. 1995. Cell Mol Biol (Noisy-le-grand). 41: 401-7. PMID: 7580834
8. A longitudinal study of the IgG antibody response to HIV-1 p17 gag protein in HIV-1+ patients with haemophilia: titre and avidity.  |  Chargelegue, D., et al. 1993. Clin Exp Immunol. 93: 331-6. PMID: 8370162
9. [HIV-1 p17 matrix protein is transported into the cell nucleus and binds with genomic viral RNA].  |  Bukrinskaia, AG., et al. 1993. Mol Biol (Mosk). 27: 49-57. PMID: 8483474
10. Overproduction, purification, and diagnostic use of the recombinant HIV-1 Gag proteins, the precursor protein p55 and the processed products p17, p24, and p15.  |  Saito, A., et al. 1995. Microbiol Immunol. 39: 473-83. PMID: 8569532
11. Antibodies to the HIV-1 p17 protein cross-react with human superoxide dismutase-2.  |  Kato, T., et al. 1997. Biochem Biophys Res Commun. 230: 184-7. PMID: 9020042
12. Coexisting members of HIV-1 p17 gene quasispecies represent proteins with distinct antigenicity and immunogenicity.  |  Birk, M., et al. 1998. AIDS. 12: 1973-81. PMID: 9814865

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-HIV-1 p55/p17 Antibody (1B2) has 0 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

HIV-1 p55/p17 Antibody (1B2) Specifications

Alternate Product Name: HIV-1 p55/p17

Product Clone Name: 1B2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁

Amino Acids:

Epitope Target: HIV-1 p55/p17

Epitope Species: HIV-1

Product Reactivity/Detection: p55 and p17

Species Reactivity/Detection: HIV-1

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IF, FCM

Vialing Information: Each vial contains 100 µg IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for HIV-1 p55/p17 Antibody (1B2): FITC: Fluoroscein

The preferred HIV-1 p17 antibody is HIV-1 p17 Antibody (17-1): sc-69723.